<DOC>
	<DOCNO>NCT01236235</DOCNO>
	<brief_summary>The purpose study describe long term ( &gt; 96 week ) efficacy safety Atazanavir-based regimen real life setting .</brief_summary>
	<brief_title>Study Long Term Outcomes Atazanavir Antiretroviral-naïve Human Immunodeficiency Virus ( HIV ) Patients Real Life Setting</brief_title>
	<detailed_description>Time perspective : Collection historical data longitudinal follow . Patients enrol 2011/2012 data collect medical chart ATV initiation date ( Feb 2008 - July 2010 ) July 2013 late ( ATV discontinuation , death , lose follow ) . Non probability sample : - Specialized HIV management center contact order recruit 15-20 site per country . - Each site enroll average 8-12 consecutive patient ( min:5 ; max:30 ) fulfil inclusion/exclusion criterion .</detailed_description>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Male Female HIV patient ≥ 18 year old ATV/RTV initiation treatment date Outpatient see routine consultation whatever reason , January 1st 2011 March 31st 2012 Commencing ATV/RTVbased regimen include least 2 nucleoside reverse transcriptase inhibitor ( NRTI ) February 1st 2008 July 31st 2010 , regardless current ARV treatment ongoing enrollment visit Patient expose begin ATV/RTV prior February 1st 2008 , July 31st 2010 without know start date ATV/RTV therapy Exposure 4 week ARV prior initiation ATV/RTV treatment Participation clinical trial ATV time initiation ATV/RTVbased regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>